Atypical Hemolytic Uremic Syndrome Clinical Trials in Iruma-gun, Saitama
2 recruitingIruma-gun, Saitama, Japan
Showing 1–2 of 2 trials
Recruiting
Phase 3
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals65 enrolled9 locationsNCT05795140
Recruiting
Phase 3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals50 enrolled31 locationsNCT05935215